NEW YORK, May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial in ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=140382&from=4 CLASS PERIOD: ...

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/ ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose critical information regarding its clinical trials, particularly related to its flagship therapeutic candidate, Navacaprant [3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased Neumora common stock starting from September 15, 2023, and they have until April 7, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims to recover losses [2]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora altered the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [3]. - The company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD, which raises concerns about the validity of the trial results [3]. - There were significant deficiencies in the Phase Two trials, particularly regarding patient population size and the male-to-female ratio, which complicates the prediction of outcomes for the KOASTAL-1 study [3].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals or entities who purchased Neumora common stock during the class period starting on or about September 15, 2023 [3]. - The deadline for shareholders to register for the class action is April 7, 2025, and they are encouraged to register to monitor the case's progress [5]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [4]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [4]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [6]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements by companies [6].

Core Viewpoint - Rosen Law Firm is urging investors of Neumora Therapeutics, Inc. to secure legal counsel before the April 7, 2025 deadline for a securities class action related to the company's IPO in September 2023 [1][2]. Group 1: Legal Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [5].